期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性髓性白血病的过去、现在和未来 被引量：1

The past, the Dresent and the future of chronic mveloidleukemia
原文传递
导出
摘要 慢性髓性白血病（CML）是以髓细胞增殖为主要特征的恶性克隆性血液疾病。一个半世纪以来，CML诊断、治疗的发展，展现的不仅是科技的进步，更彰显了科技与医术（医师）的结合，是血液恶性疾病诊疗发展的典范。
作者 黄晓军
机构地区 北京大学人民医院、北京大学血液病研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第2期89-91,共3页 Chinese Journal of Hematology
关键词 慢性髓性白血病 血液疾病 恶性疾病 细胞增殖 克隆性 CML 科技
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1National Comprehensive Cancer Network. NCCN Clinical Prac?tice Guidelines in Oncology: Chronic Myelogenous Leukemia, Y.2.2013[S/OLJ. http://www.nccn.org/professionals/physician?gls/f- fuidelines.asp#cml.
  • 2Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013 ,122(6): 872-884.
  • 3中国慢性髓性白血病诊断与治疗指南（2013年版）[J].中华血液学杂志,2013,34(5):464-470. 被引量：95
  • 4Jiang Q, Xu LP, Liu DH, et al. Imatinib results in better outcomes than HLA- identical sibling transplants in young persons with newly diagnosed chronic- phase chronic myelogenous leukemia[J]. Leukemia, 2013, 27 (12) : 2410- 2413.
  • 5Kantarjian HM, Shah NP, CortesJE, et al. Dasatinib or imatinib in newly diagnosed chronic- phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)[J]. Blood,2012, 119(5): 1123-1129.
  • 6Jiang Q, XU LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase[J]. Blood, 2011 , 117(11) :3032-3040.
  • 7Chang YJ, Huang XJ. Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts[J]. Curr Opin Hematol,2012, 19(6) :454-461.
  • 8Jiang Q, Zhao XY, Qin YZ, et al. The differences and correlations of BCR - ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia[J]. AmJ Hematol,2012 ,87( 12): 1065-1069.
  • 9Qin YZ,Jiang Q,Jiang H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL (IS) or log reduction from the baseline level?[J]. Leuk Res ,2013 ,37(9): 1035-1040.
  • 10CortesJ, Kantarjian H. How I treat newly diagnosed chronic phase CML[J]. Blood,2012,120(7):1390-1397.

二级参考文献58

  • 1黄河,蔡真,林茂芳,谢万灼,梁彬,李黎,何静松,罗依,郑伟燕,张洁,叶琇锦,胡晓蓉,陈水云,金爱云.非亲缘异基因骨髓移植治疗儿童白血病[J].中华儿科杂志,2004,42(11):835-839. 被引量：7
  • 2贺其图,时风桐,袁祖正.包头市白血病流行病学调查[J].内蒙古医学杂志,1993,13(2):3-5. 被引量：11
  • 3江倩,陈珊珊,江滨,江浩,丘镜滢,刘艳荣,张艳,秦亚溱,陆颖,黄晓军,陆道培.甲磺酸伊马替尼治疗慢性粒细胞白血病慢性期100例追踪观察[J].中华血液学杂志,2006,27(11):721-726. 被引量：39
  • 4唐正贤 孙秋云 张金桃.上海市金山县11年白血病流行病学调查[J].中华血液学杂志,1994,15(8):430-430.
  • 5National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, V. 2. 2008. [ DB/OL]. (2007-10-25). http://www, nccn. org/profes- sionals/physician-gls/f-guidelines, asp#cml.
  • 6Druker BJ, Lee SJ. Chronic myelogenous leukemia//Cancer Prin- ciples and Practice of Oncology. 2007.
  • 7NCCN Clinical Practice Guidelines in oncology TM, Chronic My- elogenous Leukemia, V. 2. 2013. [ DB/OL]. http://www, nccn. org/professionals/physician-gls/f-guidelines, asp#cml.
  • 8Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leu- kemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann 0ncol,2012,23 Suppl 7 : vii72-vii77.
  • 9Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of the European LeukemiaNet. J Clin Oncol, 2009, 27:6041-6051.
  • 10World Health Organization Classification of Tumors. Pathology and Genetic of Tumors of Haematopoietic and Lymphoid Tissue. 2008.

共引文献94

同被引文献7

引证文献1

二级引证文献2

中华血液学杂志
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部